These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34245591)

  • 21. Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be
    Jonny J; Putranto TA; Sitepu EC; Irfon R
    Expert Rev Vaccines; 2022 Aug; 21(8):1111-1120. PubMed ID: 35593184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.
    Zhou R; To KK; Wong YC; Liu L; Zhou B; Li X; Huang H; Mo Y; Luk TY; Lau TT; Yeung P; Chan WM; Wu AK; Lung KC; Tsang OT; Leung WS; Hung IF; Yuen KY; Chen Z
    Immunity; 2020 Oct; 53(4):864-877.e5. PubMed ID: 32791036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
    Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
    Front Immunol; 2020; 11():1979. PubMed ID: 32973803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
    Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M
    Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19: immunopathogenesis and Immunotherapeutics.
    Yang L; Liu S; Liu J; Zhang Z; Wan X; Huang B; Chen Y; Zhang Y
    Signal Transduct Target Ther; 2020 Jul; 5(1):128. PubMed ID: 32712629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune response scenario and vaccine development for SARS-CoV-2 infection.
    Mohammad MHS
    Int Immunopharmacol; 2021 May; 94():107439. PubMed ID: 33571745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from dermatology about inflammatory responses in Covid-19.
    Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
    Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
    Amor S; Fernández Blanco L; Baker D
    Clin Exp Immunol; 2020 Nov; 202(2):193-209. PubMed ID: 32978971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19: imbalanced cell-mediated immune response drives to immunopathology.
    Wang J; Li Q; Qiu Y; Lu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2393-2404. PubMed ID: 36069182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covid-19: Perspectives on Innate Immune Evasion.
    Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
    Front Immunol; 2020; 11():580641. PubMed ID: 33101306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.
    Dhama K; Patel SK; Pathak M; Yatoo MI; Tiwari R; Malik YS; Singh R; Sah R; Rabaan AA; Bonilla-Aldana DK; Rodriguez-Morales AJ
    Travel Med Infect Dis; 2020; 37():101755. PubMed ID: 32479816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
    Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
    J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
    Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
    Front Immunol; 2022; 13():888248. PubMed ID: 35844604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
    Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
    Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host cell-intrinsic innate immune recognition of SARS-CoV-2.
    Madden EA; Diamond MS
    Curr Opin Virol; 2022 Feb; 52():30-38. PubMed ID: 34814102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection.
    Conti P; Younes A
    J Biol Regul Homeost Agents; 2020 March-April,; 34(2):339-343. PubMed ID: 32253888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.